Advancell secured a $315 million oversubscribed Series D to advance ADVC-001, its lead radioligand therapy targeting prostate-specific membrane antigen (PSMA), and to build out late-stage manufacturing and isotope supply infrastructure. The funding underscores continued capital access for radiopharmaceutical platforms as developers prepare for larger-scale commercialization.